Stay invested in Lupin, says Sharmila Joshi

Sharmila Joshi of sharmilajoshi.com told CNBC-TV18, "What we are also seeing in the recent couple of weeks has been that the largecap pharmaceuticals has sort of underperformed some of the midcap stocks. The twin pressures on pharma continue with US Food and Drug Administration (FDA) also pricing pressure which a lot of companies have voiced and I think that is likely to stay."

She further added, "This would be the wrong price to sell Lupin. My sense is that things have bottomed out, so if one is a long-term investor, I would recommend to stay invested rather than sell and fortunately, markets are also doing fairly well. So if you were to get a whiff off a better performance from some of the larger companies, then you can continue to hold the stock."